Evidence map›Paper›PMID 28268248›Full record

ArticleInternational journal of cancer2017

Dietary glycemic and insulin scores and colorectal cancer survival by tumor molecular biomarkers.

NaNa Keum, Chen Yuan, Reiko Nishihara, Emilie Zoltick, Tsuyoshi Hamada, Alejandro Martinez Fernandez, Xuehong Zhang, Akiko Hanyuda, Li Liu, Keisuke Kosumi and 13 more

Open access · bronzeAbstract read
In one paragraph

Article in International journal of cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 4 institutions in 3 countries.

NaNa KeumDepartment of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA.ORCID 0000-0003-4671-0211
Chen YuanDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA.
Reiko NishiharaDepartment of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA.
Emilie ZoltickDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA.
Tsuyoshi HamadaDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.
Alejandro Martinez FernandezDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.
Xuehong ZhangChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
Akiko HanyudaDepartment of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA.
Li LiuDepartment of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA.
Keisuke KosumiDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.
Jonathan A NowakDivision of MPE Molecular Pathological Epidemiology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
Iny JhunDivision of MPE Molecular Pathological Epidemiology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
T Rinda SoongDivision of MPE Molecular Pathological Epidemiology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
Teppei MorikawaDepartment of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Fred K TabungDepartment of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA.ORCID 0000-0001-8193-7150
Zhi Rong QianDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.
Charles S FuchsDepartment of Medicine, Yale School of Medicine, New Haven, CT.
Jeffrey A MeyerhardtDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.
Andrew T ChanClinical and Translational Epidemiology Unit and Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA.
Kimmie NgDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.
Shuji OginoDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA.
Edward L GiovannucciDepartment of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA.
Kana WuDepartment of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA.
Harvard University · USBrigham and Women's Hospital · USThe University of Tokyo · JPYale University · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Statistical MethodsP01CA087969 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI TWOROGER, SHELLEY S · 2000 to 2019
$77.8M
Validity of Diet and Activity Measures in WomenP01CA055075 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI RIMM, ERIC B · 1991 to 2009
$41.8M
Pilot & Feasibility ProgramP30DK043351 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI RAYMOND T CHUNG · 1991 to 2026
$35.3M
Tissue and Pathology ResourcesP50CA127003 · NCI · DANA-FARBER CANCER INST · PI EL-BARDEESY, NABEEL, SELLERS, WILLIAM R · 2007 to 2023
$33.2M
Long Term Multidisciplinary Study of Cancer in Women: The Nurses Health StudyUM1CA186107 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ELIASSEN, A. HEATHER, STAMPFER, MEIR · 2014 to 2023
$22.3M
Cancer Epidemiology Cohort in Male Health ProfessionalsUM1CA167552 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI WILLETT, WALTER C. · 2012 to 2016
$11.5M
BIOCHEMICAL MARKERS IN THE NURSES'HEALTH STUDY COHORTR01CA049449 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI HANKINSON, SUSAN E · 1989 to 2008
$11.3M
Inflammation and Colorectal NeoplasiaR01CA137178 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI CHAN, ANDREW T · 2009 to 2019
$6.5M
Accelerating Transdisciplinary Epidemiology of Colorectal CancerR35CA197735 · NCI · DANA-FARBER CANCER INST · PI OGINO, SHUJI · 2015 to 2021
$6.0M
Novel randomized controlled trials of vitamin D supplementation in patients with colorectal cancer: Impact on survival and biologyR01CA205406 · NCI · DANA-FARBER CANCER INST · PI Kimmie Ng · 2017 to 2026
$4.9M
Dietary And Lifestyle Determinants Of Colon Cancer Recurrence and SurvivalR01CA118553 · NCI · YALE UNIVERSITY · PI FUCHS, CHARLES S · 2007 to 2019
$4.4M
NCATS NIH HHS UL1 TR001863NCI NIH HHS K07 CA148894NCI NIH HHS K07 CA188126NCI NIH HHS K07 CA190673NCI NIH HHS K99 CA207736NCI NIH HHS P01 CA055075NCI NIH HHS P01 CA087969NCI NIH HHS P50 CA127003NCI NIH HHS R01 CA049449NCI NIH HHS R01 CA118553NCI NIH HHS R01 CA137178NCI NIH HHS R01 CA151993NCI NIH HHS R01 CA169141NCI NIH HHS R01 CA205406NCI NIH HHS R35 CA197735NCI NIH HHS UM1 CA167552NCI NIH HHS UM1 CA186107NIDDK NIH HHS K24 DK098311NIDDK NIH HHS P30 DK043351
6 · The paper itself

Abstract

Accumulating evidence suggests that post-diagnostic insulin levels may influence colorectal cancer (CRC) survival. Yet, no previous study has examined CRC survival in relation to a post-diagnostic diet rich in foods that increase post-prandial insulin levels. We hypothesized that glycemic and insulin scores (index or load; derived from food frequency questionnaire data) may be associated with survival from specific CRC subtypes sensitive to the insulin signaling pathway. We prospectively followed 1,160 CRC patients from the Nurses' Health Study (1980-2012) and Health Professionals Follow-Up Study (1986-2012), resulting in 266 CRC deaths in 10,235 person-years. CRC subtypes were defined by seven tumor biomarkers (KRAS, BRAF, PIK3CA mutations, and IRS1, IRS2, FASN and CTNNB1 expression) implicated in the insulin signaling pathway. For overall CRC and each subtype, hazard ratio (HR) and 95% confidence interval (95% CI) for an increase of one standard deviation in each of glycemic and insulin scores were estimated using time-dependent Cox proportional hazards model. We found that insulin scores, but not glycemic scores, were positively associated with CRC mortality (HR = 1.19, 95% CI = 1.02-1.38 for index; HR = 1.23, 95% CI = 1.04-1.47 for load). The significant positive associations appeared more pronounced among PIK3CA wild-type cases and FASN-negative cases, with HR ranging from 1.36 to 1.60 across insulin scores. However, we did not observe statistically significant interactions of insulin scores with PIK3CA, FASN, or any other tumor marker (p interaction > 0.12). While additional studies are needed for definitive evidence, a high-insulinogenic diet after CRC diagnosis may contribute to worse CRC survival.

Indexed as

DietBiomarkers, TumorBlood GlucoseColorectal NeoplasmsFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticHealth PersonnelHumansInsulinMaleMultivariate AnalysisMutationNursesProportional Hazards ModelsProspective StudiesBiomarkers, TumorBlood GlucoseInsulincolorectal cancercolorectal cancer survivalFASNglycemic indexglycemic loadinsulin indexinsulin loadinsulin signaling pathwayPIK3CA

Identifiers

PMID28268248
PMCPMC5459960
OpenAlexW2592724972

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.